Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-05-08
2000-06-06
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544230, 544360, 544365, 544372, 544373, 514210, 514212, 514252, 514253, 540200, 540354, 540362, 540450, 540451, 540481, 540524, 540598, A61K 31496, C07D40106, C07D40306
Patent
active
06071915&
ABSTRACT:
This invention relates to a series of arylsubstituted piperazines, of Formula I ##STR1## pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the .alpha.-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.
REFERENCES:
patent: 4069336 (1978-01-01), Lange et al.
patent: 4841051 (1989-06-01), Shiozawa et al.
patent: 5380725 (1995-01-01), Abou-Gharbia et al.
patent: 5403847 (1995-04-01), Gluchowski et al.
patent: 5807856 (1998-09-01), Bock et al.
Barry M., Roehrborn C. (1997) Management of Benign Prostatic Hyperplasia. Annual Review. 48: 177-188.
Steers W., Zorn B. (1995) Benign Prostatic Hyperplasia, Disease-a-Month. vol. XLI No. 7 440-497.
Breslin D, Fields DW, Chou T-C, Marion DN, Kane M, Vaughan ED, and Felsen D (1993) Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. J. Urol. 149: 395-399.
Bruno JF, Whittaker J, Song J, and Berelowitz M. (1991) Molecular cloning and sequencing of a cDNA encoding a human .alpha.1A adrenergic receptor. Biochem, Biophys. Res. Commun. 179: 1485-1490.
Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, and Trendelenburg U (1994) IV. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46: 121-136.
Carruthers SG (1994) Adverse effects of .alpha.1-adrenergic blocking drugs. Drug Safety 11: 12-20.
Faure C, Gouhier C, Langer SZ, and Graham D (1995) Quantification of .alpha.1-adrenoceptor subtypes in human tissues by competitive RT-PCR analysis. Biochem. Biophys. Res. Commun. 213: 935-943.
Flavahan NA and VanHoutte PM (1986) .alpha.1-Adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol. Sci. 7: 347-349.
Ford APDW, Arredondo NF, Blue DR, Bonhaus DW, Jasper J Kava MS, Lesnick J, Pfister JR, Shieh IA, Vimont RL, Williams TJ, McNeal JE, Stamey TA, and Clarke DE (1996) RS-17053 (N-[2-(2-Cyclopropylmethoxyphenoxy)ethyl]-5-chloro-a, a-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective .alpha.1A-adrenoceptor antagonist, displays low affinity for functional .alpha.1-adrenoceptors in human prostate: Implications for adrenoceptor classification. Mol. Pharmacol. 49: 209-215.
Forray C, Bard JA, Wegzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, and Gluchowski C (1994) The .alpha.1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human .alpha.1c subtype. Mol. Pharmacol. 45: 703-708.
Gormley G, Stoner E, Bruskewitz RC et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 327: 1185-1191.
Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, and Takeda M (1994) Pharmacological evidence of distinct .alpha.1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br. J. Pharmacol. 113: 723-728.
Harrison JK, Pearson WR, and Lynch KR (1991) Molecular characterization of .alpha.1- and .alpha.2-adrenoceptors. Trends Pharmacol. Sci. 12: 62-67.
Hieble JP and Caine M (1986) Etiology of benign prostatic hyperplasia and approaches to pharacological management. Fed. Proc. 45: 2601-2603.
Hirasawa A, Horie K, Tanaka T, Takagaki K, Murai M, Yano J, and Tsujimoto G (1993) Cloning, functional expression and tissue distribution of human cDNA for the .alpha.1c-adrenergic receptor. Biochem. Biophys. Res. Commun. 195: 902-909.
Holck MI, Jones CHM, and Haeusler G (1983) Differential interactions of clonidine and methoxamine with postsynaptic .alpha.-adrenoceptors of rabbit main pulmonary artery. J. Cardiovasc. Pharm. 5: 240-248.
Lepor H and Rigaud G (1990) The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J. Urol. 143: 533-537.
Lepor H, Auerbach S, Puras-Baez A et al. (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol. 148: 1467-1474.
Lepor H (1995) .alpha.-Blockade for benign prostatic hyperplasia (BPH) J. Clin. Endocrinol. Metab. 80: 750-753.
Marshall I, Burt RP, Andersson PO, Chapple CR, Greengrass PM, Johnson GI, and Wyllie MG (1992) Human .alpha.1c-adrenoceptor: functional characterization in prostate. Br. J. Pharmacol. 107(Proc. Suppl. Dec.):327P.
Marshall I, Burt RP, and Chapple CR (1995) Noradrenaline contractions of human prostate mediated by .alpha.1A- (.alpha.1c-) adrenoceptor subtype. Br. J. Pharmacol. 115: 781-786.
Mebust WK, Holtgrewe HL, Cockett ATK, and Peters PC (1989) Transurethral prostatectomy: immediate and postoperative complication: a cooperative study of 13 participating institutions evaluating 3,885 patients.J. Urol. , 141: 243-247.
Minneman KP, Han C and Abel PW (1988) Comparison of .alpha.1-adrenergic receptor subtypes distinguished by chloroethylclonidine and WB4101. Mol. Pharmacol. 33: 509-514.
Minneman KP and Esbenshade TA (1994) .alpha.1-Adrenergic receptor subtypes. Annu. Rev. Pharmacol. Toxicol. 34: 117-133.
Morrow AL and Creese I (1986) Characterization of .alpha.1-adrenergic receptor subtypes in rat brain: A reevaluation of [3H]WB4104 and [3H]prazosin binding. Mol. Pharmacol. 29: 321-330.
Muramatsu I (1992) A pharmacological perspective of .alpha.1-adrenoceptors: subclassification and functional aspects, in .alpha.-Adrenoceptors (Fujiwara M, Sugimoto T, and Kogure K, eds.). Excerpta Medica Ltd., Tokyo, 193-202.
Muramatsu I, Oshita M, Ohmura T, Kigoshi S, Akino H, Gobara M, and Okada K (1994) Pharmacological characterization of .alpha.1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br. J. Urol. 74: 572-577.
Oesterling JE (1995) Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N. Engl. J. Med. 332: 99-109.
Price DT, Lefkowitz RJ, Caron MG, Berkowitz D, and Schwinn DA (1994) Localization of mRNA for three distinct .alpha.1-adrenergic receptor subtypes in human tissues: implications for human .alpha.-adrenergic physiology. Mol. Pharmacol. 45: 171-175.
Ramarao CS, Kincade Denker JM, Perez DM, Gaivin RJ, Riek RP, and Graham RM (1992) Genomic organization and expression of the human .alpha.1B-adrenergic receptor. J. Biol. Chem. 267: 21936-21945.
Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, Peter B, and Bailey DS (1995) Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. JPET 272: 134-142.
Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, and Bayne M (1994) Cloning, expression and characterization of human .alpha. adrenergic receptors .alpha.1A, .alpha.1B, and .alpha.1C. Biochem. Biophys. Res. Commun. 201: 1296-1304.
Weis KA, Epstein RS, Huse DM, Deverka PA and Oster G (1993) The costs of prostatectomy for benign prostatic hyperplasia. Prostate 22: 325-334.
Wennberg JE, Roos N, Sola L, Schori A, and Jaffe R (1987) Use of claims data systems to evaluate health care outcomes: mortality and reoperation following prostatectomy. JAMA 257: 933-936.
Yamada S, Tanaka C, Kimura R, and Kawabe K (1994) Alpha 1-adrenoceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists. Life Sci. 54: 1845-1854.
Jolliffe Linda
Li Xiaobing
Maryanoff Cynthia
Mulcahy Linda
Murray William
Hope Ruby T.
Kessinger Ann
Ortho-McNeil Pharmaceutical , Inc.
Shah Mukund J.
Wallen, III John
LandOfFree
Arylsubstituted piperazines useful in the treatment of benign pr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylsubstituted piperazines useful in the treatment of benign pr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylsubstituted piperazines useful in the treatment of benign pr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2213793